Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile
Datamonitor, October 2010, Pages: 98
Introduction
This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Takeda's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
Strategic insight into the prospects for Takeda over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Takeda's performance against key rivals in the prescription pharmaceutical sector
- Discover if Takeda will overcome generic competition facing its biggest selling medications
- Investigate the diverse strategies being employed by Japan's oldest and largest pharmaceutical player
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Takeda: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Chapter 3 Quarterly news update
Latest prescription pharma product news
Latest corporate news
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Chapter 7 Key products
Overview
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
Datamonitor consulting
Disclaimer
TABLE OF TABLES
Table 1: Takeda – PharmaVitae forecasts at a glance
Table 2: Takeda future product milestones, 2010–12
Table 3: Takeda product portfolio overview ($m), 2003–09
Table 4: Takeda product portfolio overview ($m), 2009–15
Table 5: Takeda prescription pharmaceutical sales by therapy area ($m), 2009–15
Table 6: Takeda prescription pharmaceutical sales by geographic region ($m), 2009–15
Table 7: Takeda launch portfolio overview ($m), 2009–15
Table 8: Takeda core portfolio overview ($m), 2009–15
Table 9: Takeda expiry portfolio overview ($m), 2009–15
Table 10: Takeda prescription pharmaceutical sales by molecule type ($m), 2009–15
Table 11: Takeda prescription pharmaceutical sales by source ($m), 2009–15
Table 12: Total Takeda sales by business unit ($m), 2003–09
Table 13: Takeda operating revenue/cost analysis ($m), 2003–09
Table 14: Takeda operating cost ratio analysis (% of total revenues), 2003–09
Table 15: Takeda operating cost ratio analysis (% of total revenues), 2009–15
Table 16: Takeda operating revenue/cost analysis ($m), 2009–15
Table 17: Takeda Key products overview
Table 18: Dexilant: overview
Table 19: Dexilant: sales forecast ($m), 2009–15
Table 20: Blopress: overview
Table 21: Blopress comp: overview
Table 22: Blopress: sales forecast ($m), 2009–15
Table 23: Blopress comp: sales forecast ($m), 2009–15
Table 24: Actos: overview
Table 25: ACTOplus met: overview
Table 26: Actos: sales forecast ($m), 2009–15
Table 27: ACTOplus met: sales forecast ($m), 2009–15
Table 28: Lupron Depot: overview
Table 29: Lupron Depot: sales forecast ($m), 2009–15
Table 30: Velcade: overview
Table 31: Velcade: sales forecast ($m), 2009–15
Table 32: Alogliptin: overview
Table 33: Alogliptin/ACTOS combo: overview
Table 34: Alogliptin: sales forecast ($m), 2009–15
Table 35: Alogliptin/ACTOS combo: sales forecast ($m), 2009–15
Table 36: Enbrel: overview
Table 37: Enbrel: sales forecast ($m), 2009–15
Table 38: Amitiza: overview
Table 39: Amitiza: sales forecast ($m), 2009–15
Table 40: Exchange rates, 2010
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer
Figure 2: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure 3: Takeda’s financial performance ($m), 2003–15
Figure 4: Major expiry product sales ($m), 2009–15
Figure 5: Oncology investment drives long-term therapeutic strategy
Figure 6: Lifecycle management of gastroenterology portfolio, sales ($m), 2009–15
Figure 7: Lifecycle management of antidiabetic portfolio, sales ($m), 2009–15
Figure 8: Takeda SWOT analysis
Figure 9: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure 10: Takeda Key product sales ($m), 2003–15
Figure 11: Takeda key sales growth drivers and resistors ($m), 2003–09
Figure 12: Takeda key sales growth drivers and resistors ($m), 2009–15
Figure 13: Takeda prescription pharmaceutical sales by therapy area ($m), 2003–15
Figure 14: Takeda prescription pharmaceutical sales by geographic region ($m), 2003–15
Figure 15: Takeda launch/core/expiry configuration ($m), 2009–15
Figure 16: Takeda prescription pharmaceutical sales by molecule type ($m), 2003–15
Figure 17: Takeda prescription pharmaceutical sales by source ($m), 2003-15
Figure 18: Takeda operating revenue/cost analysis ($m), 2003–15
Figure 19: Dexilant sales by geography and analyst consensus ($m), 2003–15
Figure 20: Blopress sales by geography and analyst consensus ($m), 2003–15
Figure 21: Blopress comp sales by geography and analyst consensus ($m), 2003–15
Figure 22: Actos sales by geography and analyst consensus ($m), 2003–15
Figure 23: ACTOplus met sales by geography and analyst consensus ($m), 2003–15
Figure 24: Lupron Depot sales by geography and analyst consensus ($m), 2003–15
Figure 25: Velcade sales by geography and analyst consensus ($m), 2003–15
Figure 26: Alogliptin sales by geography and analyst consensus ($m), 2003–15
Figure 27: Alogliptin/ACTOS combo sales by geography and analyst consensus ($m), 2003–15
Figure 28: Enbrel sales by geography and analyst consensus ($m), 2003–15
Figure 29: Amitiza sales by geography and analyst consensus ($m), 2003–15
3M
Abbott Laboratories
Alkermes Inc
Amgen Inc.
Amylin Pharmaceuticals Inc
Astellas Pharma
AstraZeneca PLC
BASF Aktiengesellschaft
Chugai Pharmaceutical Co. Ltd
Daiichi Sankyo, Ltd.
Dainippon Sumitomo Pharma Co., Ltd.
Eli Lilly and Company
GlaxoSmithKline Plc
IMS Health
Ligand Pharmaceuticals Incorporated
Medicines Company, The
Merck & Co., Inc.
Merck KGaA
Novartis AG
Pfizer Inc
Tanabe Seiyaku Co., Ltd.
TAP Pharmaceutical Products, Inc.
The Depository Trust & Clearing Corporation
Wyeth
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
